Do analysts recommend DRMA or QLGN?

Dermata Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 754.70%. Given Dermata Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Dermata Therapeutics is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, DRMA or QLGN?

Dermata Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dermata Therapeutics N/A N/A -$7.56M -$5.31 N/A Qualigen Therapeutics N/A N/A -$6.26M -$7.50 N/A

Is DRMA or QLGN more profitable?

Qualigen Therapeutics' return on equity of 0.00% beat Dermata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dermata Therapeutics N/A -127.91% -105.05% Qualigen Therapeutics N/A N/A -202.16%

Do analysts rate QLGN or INM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer QLGN or BMRA?

Biomerica has a consensus price target of $9.00, indicating a potential upside of 504.03%. Given Biomerica's higher possible upside, analysts clearly believe Biomerica is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biomerica 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate QLGN or ALZN?

Alzamend Neuro has a consensus price target of $28.00, suggesting a potential upside of 2,037.40%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, QLGN or ALZN?

Alzamend Neuro is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qualigen Therapeutics N/A N/A -$6.26M -$7.50 N/A Alzamend Neuro N/A N/A -$8.77M -$2.90 N/A

Is QLGN or ALZN more profitable?

Qualigen Therapeutics' return on equity of 0.00% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A N/A -202.16% Alzamend Neuro N/A -277.74% -200.07%

Do analysts recommend CDIO or QLGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Qualigen Therapeutics (QLGN) Competitors

$0.66 -0.01 (-1.25%)

As of 07/31/2026

Compare

QLGN vs. DRMA, INM, BMRA, ALZN, and CDIO

Should you buy Qualigen Therapeutics stock or one of its competitors? MarketBeat compares Qualigen Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Qualigen Therapeutics include Dermata Therapeutics (DRMA), InMed Pharmaceuticals (INM), Biomerica (BMRA), Alzamend Neuro (ALZN), and Cardio Diagnostics (CDIO).

How does Qualigen Therapeutics compare to Dermata Therapeutics?

Dermata Therapeutics (NASDAQ:DRMA) and Qualigen Therapeutics (NASDAQ:QLGN) are related small-cap companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Dermata Therapeutics has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Qualigen Therapeutics' return on equity of 0.00% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-127.91%	-105.05%
Qualigen Therapeutics	N/A	N/A	-202.16%

Dermata Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A

Dermata Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 754.70%. Given Dermata Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Dermata Therapeutics is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

8.7% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 21.9% of Dermata Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Dermata Therapeutics had 2 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 2 mentions for Dermata Therapeutics and 0 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.00 beat Dermata Therapeutics' score of -0.36 indicating that Qualigen Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Dermata Therapeutics	Neutral
Qualigen Therapeutics	Neutral

Summary

Dermata Therapeutics beats Qualigen Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Qualigen Therapeutics compare to InMed Pharmaceuticals?

Qualigen Therapeutics (NASDAQ:QLGN) and InMed Pharmaceuticals (NASDAQ:INM) are related small-cap companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Qualigen Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

In the previous week, Qualigen Therapeutics' average media sentiment score of 0.00 beat InMed Pharmaceuticals' score of -0.71 indicating that Qualigen Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
InMed Pharmaceuticals	Negative

3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are held by institutional investors. 1.8% of Qualigen Therapeutics shares are held by insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Qualigen Therapeutics has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. Qualigen Therapeutics' return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-202.16%
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%

Qualigen Therapeutics has higher earnings, but lower revenue than InMed Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A
InMed Pharmaceuticals	$4.94M	0.98	-$8.16M	-$2.89	N/A

Summary

Qualigen Therapeutics beats InMed Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Biomerica?

Qualigen Therapeutics (NASDAQ:QLGN) and Biomerica (NASDAQ:BMRA) are related small-cap companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Qualigen Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Biomerica has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market.

In the previous week, Biomerica had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 1 mentions for Biomerica and 0 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.00 equaled Biomerica'saverage media sentiment score.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
Biomerica	Neutral

Biomerica has a consensus price target of $9.00, indicating a potential upside of 504.03%. Given Biomerica's higher possible upside, analysts clearly believe Biomerica is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 18.0% of Biomerica shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Qualigen Therapeutics has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. Qualigen Therapeutics' return on equity of 0.00% beat Biomerica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-202.16%
Biomerica	-96.49%	-98.14%	-70.42%

Biomerica has higher revenue and earnings than Qualigen Therapeutics. Biomerica is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A
Biomerica	$4.33M	1.06	-$4.97M	-$0.89	N/A

Summary

Biomerica beats Qualigen Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Alzamend Neuro?

Qualigen Therapeutics (NASDAQ:QLGN) and Alzamend Neuro (NASDAQ:ALZN) are related small-cap companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

In the previous week, Alzamend Neuro had 3 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 3 mentions for Alzamend Neuro and 0 mentions for Qualigen Therapeutics. Alzamend Neuro's average media sentiment score of 0.17 beat Qualigen Therapeutics' score of 0.00 indicating that Alzamend Neuro is being referred to more favorably in the news media.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
Alzamend Neuro	Neutral

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 1.4% of Alzamend Neuro shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Qualigen Therapeutics' return on equity of 0.00% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-202.16%
Alzamend Neuro	N/A	-277.74%	-200.07%

Alzamend Neuro is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.90	N/A

Alzamend Neuro has a consensus price target of $28.00, suggesting a potential upside of 2,037.40%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Qualigen Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.14, suggesting that its share price is 86% less volatile than the broader market.

Summary

Alzamend Neuro beats Qualigen Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Cardio Diagnostics?

Cardio Diagnostics (NASDAQ:CDIO) and Qualigen Therapeutics (NASDAQ:QLGN) are related small-cap companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Qualigen Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. Qualigen Therapeutics' return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%
Qualigen Therapeutics	N/A	N/A	-202.16%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 13.3% of Cardio Diagnostics shares are owned by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Cardio Diagnostics' average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company	Overall Sentiment
Cardio Diagnostics	Neutral
Qualigen Therapeutics	Neutral

Cardio Diagnostics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Qualigen Therapeutics has lower revenue, but higher earnings than Cardio Diagnostics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10K	461.76	-$6.50M	-$3.38	N/A
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A

Summary

Cardio Diagnostics beats Qualigen Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Qualigen Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QLGN vs. The Competition

Export

Metric	Qualigen Therapeutics	Software Industry	Technology Sector	NASDAQ Exchange
Market Cap	$1.12M	$14.56B	$28.18B	$12.47B
Dividend Yield	N/A	3.44%	2.77%	9.45%
P/E Ratio	-0.09	130.87	79.78	24.66
Price / Sales	N/A	1,294.36	595.15	88.65
Price / Cash	N/A	43.28	46.16	59.99
Price / Book	-0.16	6.42	6.95	5.90
Net Income	-$6.26M	$365.95M	$628.91M	$336.31M
7 Day Performance	-19.41%	1.88%	0.79%	0.09%
1 Month Performance	-45.75%	-2.32%	-4.58%	-5.17%
1 Year Performance	-69.50%	6.92%	148.05%	18.61%

Qualigen Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QLGN Qualigen Therapeutics	N/A	$0.66 -1.3%	N/A	-69.5%	$1.12M	N/A	N/A	50	Gap Down
DRMA Dermata Therapeutics	2.4108 of 5 stars	$1.26 -1.6%	$10.00 +693.7%	-81.9%	$5.15M	N/A	N/A	8	News Coverage Positive News Analyst Upgrade Short Interest Decrease
INM InMed Pharmaceuticals	1.3525 of 5 stars	$1.66 +7.8%	N/A	-38.5%	$5.10M	$4.94M	N/A	10	Gap Up High Trading Volume
BMRA Biomerica	1.9147 of 5 stars	$1.61 -1.9%	$9.00 +459.0%	-52.7%	$5.07M	$5.31M	N/A	60	Positive News Short Interest Decrease
ALZN Alzamend Neuro	1.6689 of 5 stars	$1.35 +2.3%	$28.00 +1,974.1%	-40.5%	$5.02M	N/A	N/A	4	Negative News Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QLGN) was last updated on 8/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Qualigen Therapeutics (QLGN) Competitors

QLGN vs. DRMA, INM, BMRA, ALZN, and CDIO

How does Qualigen Therapeutics compare to Dermata Therapeutics?

Summary

How does Qualigen Therapeutics compare to InMed Pharmaceuticals?

Summary

How does Qualigen Therapeutics compare to Biomerica?

Summary

How does Qualigen Therapeutics compare to Alzamend Neuro?

Summary

How does Qualigen Therapeutics compare to Cardio Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QLGN vs. The Competition

Qualigen Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Qualigen Therapeutics (QLGN) Competitors

QLGN vs. DRMA, INM, BMRA, ALZN, and CDIO

How does Qualigen Therapeutics compare to Dermata Therapeutics?

Which has more risk and volatility, DRMA or QLGN?

Is DRMA or QLGN more profitable?

Which has higher valuation & earnings, DRMA or QLGN?

Do analysts recommend DRMA or QLGN?

Do insiders & institutionals believe in DRMA or QLGN?

Does the media favor DRMA or QLGN?

Summary

How does Qualigen Therapeutics compare to InMed Pharmaceuticals?

Do analysts rate QLGN or INM?

Which has more volatility & risk, QLGN or INM?

Does the media refer more to QLGN or INM?

Do insiders and institutionals have more ownership in QLGN or INM?

Is QLGN or INM more profitable?

Which has stronger valuation & earnings, QLGN or INM?

Summary

How does Qualigen Therapeutics compare to Biomerica?

Which has more volatility & risk, QLGN or BMRA?

Does the media favor QLGN or BMRA?

Do analysts prefer QLGN or BMRA?

Do insiders & institutionals believe in QLGN or BMRA?

Is QLGN or BMRA more profitable?

Which has stronger earnings & valuation, QLGN or BMRA?

Summary

How does Qualigen Therapeutics compare to Alzamend Neuro?

Does the media refer more to QLGN or ALZN?

Do insiders and institutionals hold more shares of QLGN or ALZN?

Is QLGN or ALZN more profitable?

Which has higher earnings and valuation, QLGN or ALZN?

Do analysts rate QLGN or ALZN?

Which has more volatility & risk, QLGN or ALZN?

Summary

How does Qualigen Therapeutics compare to Cardio Diagnostics?

Is CDIO or QLGN more profitable?

Do analysts recommend CDIO or QLGN?

Do institutionals & insiders hold more shares of CDIO or QLGN?

Does the media refer more to CDIO or QLGN?

Which has more risk and volatility, CDIO or QLGN?

Which has stronger valuation and earnings, CDIO or QLGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QLGN vs. The Competition

Qualigen Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools